<DOC>
	<DOCNO>NCT00472420</DOCNO>
	<brief_summary>This single arm study evaluate benefit add MabThera standard induction chemotherapy patient newly diagnose mantle cell lymphoma . The safety tolerability MabThera-containing first line regimen also assess . All patient receive MabThera ( 375mg/m2 iv ) every 3 week 8 cycle , combination standard chemotherapy . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Plus Standard Chemotherapy Patients With Previously Untreated Mantle Cell Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>histologicallyproven mantle cell lymphoma ; previously untreated disease stage II , III IV , require therapy . know hypersensitivity reaction rituximab , know antimurine antibody reactivity know hypersensitivity murine antibody ; active malignancy mantle cell lymphoma within 5 year start study , exception resect basal cell cancer , squamous cell cancer skin , situ cancer cervix ; serious disorder interfere full standard dose chemotherapy ; stage I disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>